Astrana Health, Inc. $ASTH Shares Bought by Sei Investments Co.

Sei Investments Co. raised its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 94.4% during the first quarter, HoldingsChannel reports. The firm owned 134,899 shares of the company’s stock after purchasing an additional 65,509 shares during the quarter. Sei Investments Co.’s holdings in Astrana Health were worth $3,308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. 325 Capital LLC grew its stake in shares of Astrana Health by 54.0% during the 4th quarter. 325 Capital LLC now owns 1,839,076 shares of the company’s stock worth $45,627,000 after purchasing an additional 645,123 shares during the period. State Street Corp raised its position in shares of Astrana Health by 6.2% during the 4th quarter. State Street Corp now owns 1,675,516 shares of the company’s stock worth $41,570,000 after purchasing an additional 98,064 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Astrana Health by 12.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,368,079 shares of the company’s stock valued at $33,545,000 after acquiring an additional 152,267 shares in the last quarter. Geode Capital Management LLC boosted its stake in Astrana Health by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock worth $25,513,000 after purchasing an additional 12,212 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Astrana Health by 418.3% during the 4th quarter. Wellington Management Group LLP now owns 738,853 shares of the company’s stock valued at $18,331,000 after acquiring an additional 596,293 shares in the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Wall Street Analyst Weigh In

ASTH has been the subject of a number of research analyst reports. Barclays increased their price objective on shares of Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday. Robert W. Baird set a $45.00 price target on Astrana Health in a research note on Friday, May 8th. TD Cowen lifted their price objective on Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Weiss Ratings raised Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 1st. Finally, Wall Street Zen raised Astrana Health from a “hold” rating to a “buy” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.29.

Astrana Health Stock Performance

Shares of ASTH stock opened at $35.76 on Friday. Astrana Health, Inc. has a 12-month low of $18.08 and a 12-month high of $51.60. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.20. The stock has a 50 day simple moving average of $41.36 and a 200-day simple moving average of $32.47. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 43.61 and a beta of 0.87.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.29 by $0.45. Astrana Health had a net margin of 1.05% and a return on equity of 10.43%. The firm had revenue of $965.10 million for the quarter, compared to analysts’ expectations of $949.21 million. During the same period in the previous year, the business earned $0.42 earnings per share. Astrana Health’s revenue for the quarter was up 55.6% compared to the same quarter last year. On average, equities analysts forecast that Astrana Health, Inc. will post 1.18 EPS for the current year.

Key Headlines Impacting Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Astrana Health reported non-GAAP earnings of $0.40 per share, up from $0.19 a year earlier and above the $0.31 consensus estimate. A separate report cited $0.80 in EPS versus a $0.34 estimate, reflecting differences between reported and adjusted measures. ASTH Q2 Earnings Top Estimates
• Positive Sentiment: Revenue continued to grow rapidly. Second-quarter revenue reached approximately $972.5 million, an increase of 48.5% year over year. Management and analysts highlighted operating leverage, technology investments and artificial intelligence initiatives as potential drivers of future profitability. ASTH Q2 Deep Dive
• Positive Sentiment: Third-quarter revenue guidance points to continued expansion. Astrana Health forecast revenue of $1.00 billion to $1.03 billion for the third quarter, supporting expectations for sustained growth. ASTH Third-Quarter Revenue Guidance
• Neutral Sentiment: Full-year revenue guidance was maintained at $3.8 billion to $4.1 billion. The midpoint is broadly consistent with the roughly $4.0 billion analyst consensus, suggesting no major change to the outlook. Astrana Health Second-Quarter Results
• Negative Sentiment: Quarterly revenue was below expectations. Revenue of approximately $972.5 million trailed the $985.6 million consensus estimate. Astrana Health also continues to operate with a thin net margin, making execution and cost control important to the stock’s valuation. Astrana Health Earnings Report

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.